I-Mab's stock soars after AbbVie collaboration, which could be worth nearly $2 billionMarket Watch • 09/04/20
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led ConsortiumPRNewsWire • 09/04/20
AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology TherapyPRNewsWire • 09/04/20
I-Mab's (IMAB) CEO Joan Huaqiong Shen on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/31/20
I-Mab Reports Financial Results for the Six Months Ended June 30 and Provides Corporate UpdatePRNewsWire • 08/31/20
I-Mab Announces First Patient Dosed in Phase 1b Study of Plonmarlimab in Rheumatoid Arthritis in ChinaPRNewsWire • 08/17/20
China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone DeficiencyPRNewsWire • 08/04/20
I-Mab Drives Commercialization Strategy with Appointment of Ivan Yifei Zhu as Chief Commercial OfficerPRNewsWire • 07/28/20
I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific Antibody Program at the 2020 American Association for Cancer Research Virtual Meeting IIPRNewsWire • 06/12/20